|Day Low/High||86.90 / 87.01|
|52 Wk Low/High||19.62 / 87.01|
Data Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Data Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting --
Addition Strengthens Leadership Team and Supports Continued Advancement and Expansion of Immunotherapy Pipeline
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Cramer is a big fan of Bristol-Myers, says American Tower is a bargain and prefers Red Hat over Hortonworks.
Cramer will be watching earnings from retailers Urban Outfitters, Home Depot and Wal-Mart.
Juno Therapeutics (JUNO) shares are rising after the company beat analysts first quarter net loss expectations.
The CNBC 'Fast Money' traders discuss bonds and utility stocks ahead of the potential interest rate hike, while also looking ahead to next week's earnings results.
Data Presented at American Association for Cancer Research (AACR) Annual Meeting 2015
Shares of Juno Therapeutics (JUNO) were down in late morning trading Monday after so-called CAR-T cellular therapies for solid tumors showed mediocre results at a conference on Sunday.
The shares of a number of companies that are developing CAR-T cancer therapies are falling following the annual meeting of the American Association for Cancer Research.
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
Cramer is staying away from Juno Therapeutics and Foundation Medicine.
It's time to accept the fact the futures are often wrong, Cramer says.
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.